REFERENCES
- USPHS/IDSA Prevention of Opportunistic Infections Work-ing Group. 1999 USPHS/IDSA guidelines for the preven-tion of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000; 30\(suppl 1):S29–65.
- Guggenbichler JP, Kastner U. Influence on macrolide anti-biotics on the oral flora [abstract]. First World Congress of Pediatric Infectious Diseases; December 4–6, 1996; Acapulco, Mexico.
- Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Strep-tococcus pneumoniae. Clin Infect Dis. 1997;24:356–362.
- Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Manual of Clinical Microbiology. 6th ed. Washington, DC: American Society of Microbiology; 1995: 282-298, 299–307, 556–565.
- National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: NCCLS; 1998. Eighth Informational Supplement M100-58. Vol. 18, No. 1.
- National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 4th ed. Wayne, PA: NCCLS; 1997. Approved Standard, M7-A4. Vol 17. No. 2.
- Furrer H, Telenti A, Rossi M, Ledergerber B. Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS. 2000;14:1409–1412.
- El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 2000;342:1085–1092.
- Currier JS, Williams PL, Koletar SL, et al. Discontinuation of MAC prophylaxis for subjects with antiretroviral therapy induced CD4 increases: A randomized, double-blind, pla-cebo controlled trial. Ann Intern Med. 2000;133:493–503.
- Bauernfeind A, Jungwirth R, Eberlein E. Comparative phar-macodynamics of clarithromycin and azithromycin against respiratory pathogens. Infection. 1995;23:316–321.
- Padilla-Raygoza N, Figueroa-Ferrari RC. Clarithromycin vs. azithromycin in the management of streptococcal pharyn-gotonsillitis [abstract]. First World Congress of Pediatric Infectious Diseases; December 4–6, 1996; Acapulco, Mexico.
- Craig WA, Andes D. Pharmacokinetics and pharmacody-namics of antibiotics in otitis media. Pediatr Infect Dis J. 1996;15:255–259.
- Tait-Kamradt A, Davies T, Cronan M, Jacobs MR, Appelbaum PC, Sutcliffe J. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumo-coccal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother. 2000;44:2118–2125.
- Oster P, Zanchi A, Cresti S, et al. Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates. Antimicrob Agents Chemother. 1999;43:2510–2512.
- Thornsberry C, Ogilvie PT, Holley HP Jr, Sahm DF. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective US study. Antimicrob Agents Chemother. 1999;43:2612–2623.
- Zhanel GG, Karlowsky JA, Palatnick L, Vercaigne L, Low DE, Hoban DJ. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: Results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group. Antimicrob Agents Chemother. 1999;43:2504–2509.
- Gray GC, McPhate DC, Leinonen M, et al. Weekly oral azithromycin as prophylaxis for agents causing acute res-piratory disease. Clin Infect Dis. 1998;26:103–110.